Who We Are

A Dedicated Team of Professionals

Tesaro is an oncology-focused biopharmaceutical company.

learn about Tesaro

Tesaro is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.

learn more

Our Strategy

Executing on Our Vision

Our pipeline is sourced through business development and licensing.

learn about our Strategy

The TESARO team has a track record of success in identifying, acquiring, developing and commercializing oncology therapeutics and supportive care products that make a meaningful difference in the lives of patients.

learn more

Our Pipeline

Developing New Therapies

Our product portfolio currently consists of multiple promising oncology-related product candidates.

learn about our Pipeline

Rolapitant IV is currently being evaluated for bioequivalence to oral rolapitant. Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor, currently being studied for the treatment of ovarian and breast cancers. TSR-011 is a potent, orally available ALK (anaplastic lymphoma kinase) inhibitor, with potential applications in a variety of oncology indications.

learn more


We have compiled a number of online resources with current information about cancer research, education, clinical trials and support groups that may be useful to patients and their caregivers.

Culture & Careers

Tesaro is seeking passionate, collaborative professionals to join our team. Our culture supports innovative thinking, the pursuit of excellence, and the sharing of ideas. Refer to our Careers section for a complete list of opportunities.

You are now leaving this website. If you would like to continue, click Continue.